Loading...
Loading...
- HC Wainwright initiated coverage on NRx Pharmaceuticals Inc NRXP with a Buying rating and a price target of $2.
- Earlier today, the FDA declined to issue an Emergency Use Authorization for NRx's Zyesami for a subgroup of patients who also received Gilead Sciences Inc's GILD remdesivir in addition to Zyesami.
- The analyst is bullish on:
- Significant potential for NRX-101 for bipolar depressed patients that can rapidly stabilize patients with suicidal ideation and behavior. "We believe NRx's focus on treatments for bipolar depression with SIB makes NRx a leader in drug development in this field," HC Wainwright notes.
- Zyesami's nascent value as a novel potential therapy for acute and chronic lung disorders.
- "We believe uncertainty in the Zyesami clinical program has been priced into NRx stock, representing a value proposition ahead of key clinical milestones that could potentially lead to NRX-101 approval in 2024", the analysts added.
- Price Action: NRXP shares are down 5.75% at $0.57 during the market session on the last check Friday.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in